<DOC>
	<DOCNO>NCT01688882</DOCNO>
	<brief_summary>To evaluate safety efficacy QGE031 versus placebo patient bullous pemphigoid . Efficacy assess reduction disease activity . How QGE031 break body impact different blood tissue marker also explore .</brief_summary>
	<brief_title>Safety , Efficacy PK/PD QGE031 v . Placebo Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment</brief_title>
	<detailed_description>This study plan divide 2 distinct part . Part 1 multicenter , randomize , placebo-controlled study evaluate efficacy , safety , PK PD multiple , subcutaneous dos QGE031 treatment patient BP disease refractory oral steroid treatment . Patients treat QGE031 placebo 2:1 ratio . Part 2 study plan multi-center , open label , dose range find study evaluate efficacy , safety , PK PD multiple , subcutaneous dos QGE031 treatment patient BP disease refractory oral steroid treatment . This study stop Part 1 complete terminate predefined criterion efficacy reach ( &gt; 50 % good placebo )</detailed_description>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<criteria>Patients diagnose bullous pemphigoid Stable dose prednisone 10mg per day great 1 mg/kg/day Weigh 40120kg total IgE level 5000 IU/mL Use rituximab within 1 year Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>bullous pemphigoid</keyword>
	<keyword>QGE031</keyword>
</DOC>